Discover trends, market shifts, and competitive outlooks for the emphysema industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What Are the Projected Market Size and Growth Rates for the Emphysema Market From 2025 To 2029?
In the recent years, there has been a significant growth in the emphysema market size. The market value is expected to expand from $4.74 billion in 2024 to $4.99 billion in the subsequent year, 2025, with a compound annual growth rate (CAGR) of 5.2%. The notable growth during the historic period can be linked to the rise in respiratory ailments, an aging population, increased smoking habits, escalating levels of air pollution, growing government initiatives, and a surge in the population indulging in tobacco smoking.
Predictions for the market size of emphysema suggest a consistent growth in the upcoming years, rising to an estimated $6.05 billion in 2029 with a compound annual growth rate (CAGR) of 4.9%. This projected rise during the forecast period can be linked to increasing healthcare expenditures, escalating environmental pollution, rising demand for diagnostic medical equipment, increasing vehicular trafficking, and a growing preference for minimally invasive procedures. The predictive period also indicates a trend towards new inhalation devices, strategic partnerships, personalized medicinal approaches, telemedicine, progress in inhalation therapies, and general medical advancements.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21956&type=smp
What Are the Primary Drivers Supporting the Market Growth of the Emphysema Market?
The emphysema market is anticipated to grow due to the rising incidence of respiratory infections. These infections, which can affect all parts of the respiratory system such as the sinuses, throat, airways, and lungs, are becoming more common due to factors like pollution, climate change, urbanization, development of drug resistance, and new pathogens. These infections can worsen emphysema by causing inflammation and increased airway obstruction, leading to tissue damage and impaired lung function. For example, the Centers for Disease Control and Prevention, a government agency based in the U.S., reported in November 2024 that there was a 15.6% increase in tuberculosis (TB) cases from 8,332 in 2022 to 9,633 in 2023, with the incidence rate also rising 15.0% from 2.5 to 2.9 per 100,000 persons. Consequently, the upward trend of respiratory infections is contributing to the expansion of the emphysema market.
Which Primary Segments of the Emphysema Market Are Driving Growth and Industry Transformations?
The emphysema market covered in this report is segmented –
1) By Type: Centrilobular, Panlobular
2) By Treatment: Medication, Therapy, Surgery, Other Treatments
3) By Diagnosis: Imaging Test, Lung Function Test, Other Diagnosis
4) By Complications: Chest Infections, Collapsed Lung, Heart Problems, Lungs Hole, Other Complications
5) By End-user: Hospitals And Clinics, Surgical Center, Other End-users
Subsegments:
1) By Centrilobular: Mild Centrilobular Emphysema, Moderate Centrilobular Emphysema, Severe Centrilobular Emphysema
2) By Panlobular: Mild Panlobular Emphysema, Moderate Panlobular Emphysema, Severe Panlobular Emphysema
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21956&type=smp
Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Emphysema Market?# Market?
North America was the largest region in the emphysema market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the emphysema market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Most Significant Market Trends in the Emphysema Market?
Leading organizations in the emphysema market are concentrating on medical advancements, including inhalable dual inhibitors for phosphodiesterase 3 and 4, in an effort to deliver sophisticated treatments that progress lung function, moderate inflammation, and support overall disease management, thereby enhancing respiratory health and life quality. An inhalable dual inhibitor for phosphodiesterase 3 and 4 is a specific type of treatment that hones in on and neutralizes both phosphodiesterase enzymes in the lungs, subsequently easing the airways and lessening inflammation, thereby enhancing breathing in conditions such as chronic obstructive pulmonary disease. For example, Verona Pharma plc, a pharma company based in the UK, introduced Ohtuvayre (ensifentrine) in June 2024 – the initial inhalable dual PDE3 and PDE4 inhibitor to be approved by the US-based federal agency, the Food and Drug Administration, for the sustaining treatment of chronic obstructive pulmonary ailments such as emphysema. This was the first innovative inhalable therapy in over two decades. The medication, featuring both bronchodilator and anti-inflammatory effects, is set for distribution via specialty pharmacies.
View the full report here:
https://www.thebusinessresearchcompany.com/report/emphysema-global-market-report
What Parameters Are Used to Define the Emphysema Market?
Emphysema is a chronic lung disease that damages the air sacs (alveoli) in the lungs, leading to difficulty in breathing. It is a form of chronic obstructive pulmonary disease (COPD) and is primarily caused by smoking or long-term exposure to air pollutants. As the alveoli become weakened and lose their elasticity, air gets trapped, making it harder for the lungs to expel carbon dioxide and take in fresh oxygen. This results in shortness of breath, chronic cough, and reduced lung function over time.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21956
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model